Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet

Inclusion Criteria:

- Moderate to severe palmar plantar psoriasis based on physician's global assessment
(PGA).

- Between 18 and 70 years of age

- Negative urine pregnancy test at screening and at baseline

- Sexually active men and women of child-bearing potential must agree to use a
medically accepted form of contraception (birth control) during the exclusionary
medicine wash-out period and throughout the study.

- Ability to self inject study drug or have a designee who can do so

- Capable of understanding and giving written voluntary informed consent

Exclusion Criteria:

- Previous treatment with Enbrel® (etanercept) or similar drugs

- Receipt of investigational drugs or "biologics" within 4 weeks of the screening
visit.

- Evidence of skin conditions (e.g. eczema) other than psoriasis that would interfere
with evaluations of the study medication.

- Receipt of any biologic medication within the previous 6 months that resulted in a
decreased white blood cell count (cells to help fight infections)

- Ultraviolet light treatment (e.g. UVB, PUVA) within one month prior to study drug
initiation.

- Receipt of immune-suppressing drugs other than Rheumatrex® (methotrexate) or
Soriatane® (acetretin) within 4 weeks prior to the first dose of study drug.
Medications you would not be allowed to take during this study include for example,
Cytoxan® (cyclosporine), Imuran® (azathioprine), or Sulfazine® (sulfasalazine). If
you remain on Rheumatrex® (methotrexate) (≤25 mg/week) or Soriatane® (acitretin) (≤50
mg/day), you must be considered to have inadequate disease control in the opinion of
the investigator based on physician's global assessment. You must have been on a
stable dose of systemic treatment for at least 1 month prior to the start of the
study medication. You will be required to maintain a stable dose of the systemic
treatment throughout the study.

- Use of topical steroids in the past 14 days unless they have been used for longer
than 14 days and the severity of disease allows entry into study.

- Systemic steroid use (prednisone, etc).

- Prior or concurrent use of Cytoxan® (cyclophosphamide).

- Elevated liver tests; red blood cell count less than normal; decreased platelet count
(cells to help with blood clotting); decreased white blood cell count (cells to fight
infection); kidney insufficiency

- Any severe adverse event, infection or abnormal laboratory value at the time of the
screening visit that would preclude participation in the study

- Presence of a severe infection, less than 30 days prior to the screening visit or
between the screening visit and the first dose of study drug

- Pregnant or breast-feeding females.

- Significant concurrent medical diseases including: Uncompensated congestive heart
failure (heart is unable to pump as normal): Myocardial infarction (heart attack)
within 12 months of screening period; Unstable or stable angina pectoris (chest pains
related to your heart); Uncontrolled high blood pressure

- Severe lung disease requiring medical or oxygen therapy

- History of cancer (other than surgically removed skin cancer and in situ cervical
cancer) within 5 years of the screening visit

- History of tuberculosis

- Known to be HIV positive

- Rheumatoid arthritis

- Any neurologic demyelinating disease (such as multiple sclerosis or any neurologic
disease causing loss of sensation or loss of normal movement) or seizure disorder

- Current or history of psychiatric disease that would interfere with ability to comply
with the study protocol or give informed consent.

- History of alcohol or drug abuse.

- Not up-to-date with all immunizations in agreement with the current immunization
guidelines

- Significant exposure to the varicella virus (chicken pox)

- Guttate or generalized pustular psoriasis

- Surgery or trauma within a month of baseline considered by the investigator to
represent a significant risk or interfere with patient evaluation.